4.6 Article

Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression

Journal

PLOS GENETICS
Volume 13, Issue 3, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pgen.1006589

Keywords

-

Funding

  1. TPS [1K08CA148912]

Ask authors/readers for more resources

Breast cancer, the second leading cause of cancer death of women worldwide, is a heterogenous disease with multiple different subtypes. These subtypes carry important implications for prognosis and therapy. Interestingly, it is known that these different subtypes not only have different biological behaviors, but also have distinct gene expression profiles. However, it has not been rigorously explored whether particular transcriptional isoforms are also differentially expressed among breast cancer subtypes, or whether transcript isoforms from the same sets of genes can be used to differentiate subtypes. To address these questions, we analyzed the patterns of transcript isoform expression using a small set of RNA-sequencing data for eleven Estrogen Receptor positive (ER+) subtype and fourteen triple negative (TN) subtype tumors. We identified specific sets of isoforms that distinguish these tumor subtypes with higher fidelity than standard mRNA expression profiles. We found that alternate promoter usage, alternative splicing, and alternate 3'UTR usage are differentially regulated in breast cancer subtypes. Profiling of isoform expression in a second, independent cohort of 68 tumors confirmed that expression of splice isoforms differentiates breast cancer subtypes. Furthermore, analysis of RNAseq data from 594 cases from the TCGA cohort confirmed the ability of isoform usage to distinguish breast cancer subtypes. Also using our expression data, we identified several RNA processing factors that were differentially expressed between tumor subtypes and/or regulated by estrogen receptor, including YBX1, YBX2, MAG OH, MAGOHB, and PCBP2. RNAi knock-down of these RNA processing factors in MCF7 cells altered isoform expression. These results indicate that global dysregulation of splicing in breast cancer occurs in a subtype-specific and reproducible manner and is driven by specific differentially expressed RNA processing factors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Correction Biotechnology & Applied Microbiology

Butler enables rapid cloud-based analysis of thousands of human genomes (vol 79, pg 134, 2019)

Sergei Yakneen, Sebastian M. Waszak, Michael Gertz, Jan O. Korbel, Brice Aminou, Javier Bartolome, Keith A. Boroevich, Rich Boyce, Angela N. Brooks, Alex Buchanan, Ivo Buchhalter, Adam P. Butler, Niall J. Byrne, Andy Cafferkey, Peter J. Campbell, Zhaohong Chen, Sunghoon Cho, Wan Choi, Peter Clapham, Brandi N. Davis-Dusenbery, Francisco M. De La Vega, Jonas Demeulemeester, Michelle T. Dow, Lewis Jonathan Dursi, Juergen Eils, Roland Eils, Kyle Ellrott, Claudiu Farcas, Francesco Favero, Nodirjon Fayzullaev, Vincent Ferretti, Paul Flicek, Nuno A. Fonseca, Josep Ll. Gelpi, Gad Getz, Bob Gibson, Robert L. Grossman, Olivier Harismendy, Allison P. Heath, Michael C. Heinold, Julian M. Hess, Oliver Hofmann, Jongwhi H. Hong, Thomas J. Hudson, Barbara Hutter, Carolyn M. Hutter, Daniel Hubschmann, Seiya Imoto, Sinisa Ivkovic, Seung-Hyup Jeon, Wei Jiao, Jongsun Jung, Rolf Kabbe, Andre Kahles, Jules N. A. Kerssemakers, Hyung-Lae Kim, Hyunghwan Kim, Jihoon Kim, Youngwook Kim, Kortine Kleinheinz, Michael Koscher, Antonios Koures, Milena Kovacevic, Chris Lawerenz, Ignaty Leshchiner, Jia Liu, Dimitri Livitz, George L. Mihaiescu, Sanja Mijalkovic, Ana Mijalkovic Lazic, Satoru Miyano, Naoki Miyoshi, Hardeep K. Nahal-Bose, Hidewaki Nakagawa, Mia Nastic, Steven J. Newhouse, Jonathan Nicholson, Brian D. O'Connor, David Ocana, Kazuhiro Ohi, Lucila Ohno-Machado, Larsson Omberg, B. F. Francis Ouellette, Nagarajan Paramasivam, Marc D. Perry, Todd D. Pihl, Manuel Prinz, Montserrat Puiggros, Petar Radovic, Keiran M. Raine, Esther Rheinbay, Mara Rosenberg, Romina Royo, Gunnar Ratsch, Gordon Saksena, Matthias Schlesner, Solomon I. Shorser, Charles Short, Heidi J. Sofia, Jonathan Spring, Lincoln D. Stein, Adam J. Struck, Grace Tiao, Nebojsa Tijanic, David Torrents, Peter Van Loo, Miguel Vazquez, David Vicente, Jeremiah A. Wala, Zhining Wang, Sebastian M. Waszak, Joachim Weischenfeldt, Johannes Werner, Ashley Williams, Youngchoon Woo, Adam J. Wright, Qian Xiang, Liming Yang, Denis Yuen, Christina K. Yung, Junjun Zhang, Jan O. Korbel

NATURE BIOTECHNOLOGY (2023)

Article Medicine, Research & Experimental

BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection

Christina A. Clarke, Kathryn Lang, Girish Putcha, Jonathan P. Beer, Maude Champagne, Andrea Ferris, James H. Godsey, Robert L. Grossman, Jody M. Hoyos, Donald J. Johann, Nancy Krunic, Peter Kuhn, Jerry S. H. Lee, Tara Maddala, Marielena Mata, Jeremiah McDole, Omar Perez, Howard Scher, Mark D. Stewart, Seema Singh Bhan, Qu Zhang, Lauren C. Leiman

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Article Hematology

Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms

Andrew J. Shih, Tomi Jun, Andrew D. Skol, Riyue Bao, Lei Huang, Sapana Vora, Megan E. McNerney, Eric A. Hungate, Michelle M. Le Beau, Richard A. Larson, Aaron Elliott, Hsiao-Mei Lu, Robert Huether, Felicia Hernandez, Friedrich Stolzel, James M. Allan, Kenan Onel

Summary: Some patients with therapy-related myeloid neoplasms (t-MN) may have unsuspected inherited cancer predisposition syndrome (CPS). A set of clinical criteria has been proposed to identify t-MN patients with high risk of CPS (HR-CPS). Among the identified HR-CPS patients, 37% had pathogenic or likely pathogenic variants, compared to 0% in the low-risk CPS patients. These simple clinical criteria help identify t-MN patients most likely to benefit from genetic testing for inherited CPS.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Oncology

Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma

Shan Wang, Xiaofang Huo, Yiping Yang, Yingxi Mo, Rahul K. Kollipara, Ralf Kittler

Summary: The deubiquitinase USP9X stabilizes EWS-FLI1 protein expression in Ewing sarcoma, and its inhibitor WP1130 can rapidly degrade EWS-FLI1 and inhibit the growth of Ewing sarcoma cells and tumors.

CANCER LETTERS (2023)

Review Oncology

Case Studies for Overcoming Challenges in Using Big Data in Cancer

Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis D. Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundam, Thoma O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo H. Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava

Summary: The analysis of big healthcare data has great potential in advancing oncology drug development and patient treatment in precision medicine. However, challenges exist in organizing, sharing, integrating, and making data accessible. This review presents five case studies showcasing successful approaches to addressing these challenges and emphasizes the need for data sharing and utilization to advance cancer research and treatment.

CANCER RESEARCH (2023)

Review Oncology

Challenges to Using Big Data in Cancer

Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava

Summary: Big data in healthcare, including electronic health records, medical imaging, genomic sequencing, payor records, and data from pharmaceutical research, wearables, and medical devices, can provide unprecedented understanding of diseases and their treatment. However, challenges such as interoperability, data quality, and data privacy need to be addressed to fully leverage the potential of big data in medicine. Organizations sharing data in a precompetitive manner, establishing agreements on data quality standards, and implementing universal and practical data privacy principles are key to realizing the benefits of big data in healthcare.

CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells

Ningfei An, Saira Khan, Molly K. K. Imgruet, Lia Jueng, Sandeep Gurbuxani, Megan E. E. McNerney

Summary: -7/del(7q) is commonly found in myeloid neoplasms. CUX1, located on 7q22, is a transcription factor associated with poor prognosis when mutated. CUX1 deficiency and oncogenic RAS mutations are found to be linked and promote leukemogenesis. This research indicates a potential therapy for malignancies with CUX1 inactivation.

ONCOGENE (2023)

Article Oncology

ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma

Anne -Florence Blandin, Ross Giglio, Maya Srikanth Graham, Guadalupe Garcia, Seth Malinowski, Jared K. Woods, Shakti Ramkissoon, Lori Ramkissoon, Frank Dubois, Kathleen Schoolcraft, Jessica Tsai, Dayle Wang, Robert Jones, Jayne Vogelzang, Kristine Pelton, Sarah Becker, Fiona Watkinson, Claire Sinai, Elizabeth F. Cohen, Matthew A. Booker, Michael Y. Tolstorukov, Veerle Haemels, Liliana Goumnerova, Karen Wright, Mark Kieran, Katie Fehnel, David Reardon, Arnault Tauziede-Espariat, Rishi Lulla, Benjamin Carcamo, Stanley Chaleff, Alain Charest, Frederik De Smet, Azra H. Ligon, Adrian Dubuc, Melanie Pages, Pascale Varlet, Patrick Y. Wen, Brian M. Alexander, Susan Chi, Sanda Alexandrescu, Ralf Kittler, Robert Bachoo, Pratiti Bandopadhayay, Rameen Beroukhim, Keith L. Ligon

Summary: This study comprehensively analyzed ALK expression and genomic aberrations in 371 glioblastomas and validated the abnormalities in vitro and in vivo. The findings showed that ALK aberrations were present in 12% of gliomas across a wide age range and ALK fusions were more common in congenital/infant glioblastomas. ALK fusions promoted pathways related to tumor transformation and responded well to ALK inhibitors, supporting their use in clinical trials for glioblastomas in different age groups.

CLINICAL CANCER RESEARCH (2023)

Article Computer Science, Information Systems

Building a collaborative cloud platform to accelerate heart, lung, blood, and sleep research

Stan Ahalt, Paul Avillach, Rebecca Boyles, Kira Bradford, Steven Cox, Brandi Davis-Dusenbery, Robert L. Grossman, Ashok Krishnamurthy, Alisa Manning, Benedict Paten, Anthony Philippakis, Ingrid Borecki, Shu Hui Chen, Jon Kaltman, Sweta Ladwa, Chip Schwartz, Alastair Thomson, Sarah Davis, Alison Leaf, Jessica Lyons, Elizabeth Sheets, Joshua C. Bis, Matthew Conomos, Alessandro Culotti, Thomas Desain, Jack Digiovanna, Milan Domazet, Stephanie Gogarten, Alba Gutierrez-Sacristan, Tim Harris, Ben Heavner, Deepti Jain, Brian O'Connor, Kevin Osborn, Danielle Pillion, Jacob Pleiness, Ken Rice, Garrett Rupp, Arnaud Serret-Larmande, Albert Smith, Jason P. Stedman, Adrienne Stilp, Teresa Barsanti, John Cheadle, Christopher Erdmann, Brandy Farlow, Allie Gartland-Gray, Julie Hayes, Hannah Hiles, Paul Kerr, Chris Lenhardt, Tom Madden, Joanna O. Mieczkowska, Amanda Miller, Patrick Patton, Marcie Rathbun, Stephanie Suber, Joe Asare

Summary: The NHLBI BioData Catalyst (BDC) is a community-driven ecosystem developed by the National Heart, Lung, and Blood Institute. It provides researchers with access to large-scale datasets and computational resources for precision medicine research. The BDC offers secure, cloud-based workspaces, authentication and authorization systems, search functionalities, tools and workflows, and innovative features to meet the needs of the research community. It has also played a significant role in accelerating research on the COVID-19 pandemic.

JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2023)

Article Biochemical Research Methods

Towards self-describing and FAIR bulk formats for biomedical data

Michael Lukowski, Andrew Prokhorenkov, Robert L. Grossman

Summary: We introduce a self-describing serialized format called Portable Format for Biomedical (PFB) data for bulk biomedical data. PFB is based on Avro and includes a data model, a data dictionary, the data itself, and pointers to third party controlled vocabularies. Each data element in the data dictionary is associated with a third party controlled vocabulary for easier harmonization of PFB files. We also introduce an open source SDK called PyPFB for creating, exploring and modifying PFB files. Experimental studies show improved performance of importing and exporting bulk biomedical data in the PFB format compared to JSON and SQL formats.

PLOS COMPUTATIONAL BIOLOGY (2023)

Editorial Material Multidisciplinary Sciences

Ten lessons for data sharing with a data commons

Robert L. Grossman

Summary: A data commons is a cloud-based data platform that allows a community to manage, analyze, and share data. It enables research communities to utilize cloud computing for large-scale data management and analysis, and securely share data, thereby accelerating research progress.

SCIENTIFIC DATA (2023)

Article Medicine, Research & Experimental

Global chromatin landscapes identify candidate noncoding modifiers of cardiac rhythm

Samadrita Bhattacharyya, Rahul K. Kollipara, Gabriela Orquera-Tornakian, Sean Goetsch, Minzhe Zhang, Cameron Perry, Boxun Li, John M. Shelton, Minoti Bhakta, Jialei Duan, Yang Xie, Guanghua Xiao, Bret M. Evers, Gary C. Hon, Ralf Kittler, Nikhil V. Munshi

Summary: A comprehensive CCS-enriched CRE database named CCS-ATAC was established for studying CCS-wide and component-specific regulatory functions. CCS component-specific gene regulatory networks (GRNs) were constructed using transcription factor (TF) motifs, and specific TF sub-networks were identified and confirmed. CCS-ATAC was leveraged to improve annotation of existing human variants related to cardiac rhythm, and a potential dysregulated enhancer-target pair by a specific SNP was nominated.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Meeting Abstract Oncology

Delineating molecular vulnerabilities of ATM mutant prostate cancers

Mia Hofstad, Lan Yu, Andrea Woods, Zoi Sychev, Collin Gilbreath, Xiaofang Huo, Ralf Kittler, Justin M. Drake, Ganesh V. Raj

CANCER RESEARCH (2023)

Meeting Abstract Oncology

ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma

Anne-Florence Blandin, Ross Giglio, Maya Srikanth Graham, Guadalupe Garcia, Seth Malinowski, Jared K. Woods, Shakti Ramkissoon, Lori Ramkissoon, Frank Dubois, Kate Schoolcraft, Jessica W. Tsai, Dayle K. Wang, Robert Jones, Jayne Vogelzang, Kristine Pelton, Sarah Becker, Fiona Watkinson, Claire Sinai, Elizabeth Cohen, Matthew Booker, Michael Tolstorukov, Veerle Haemels, Liliana Goumnerova, Karen Wright, Mark Kieran, Katie Fehnel, David Reardon, Arnault Tauziede-Espariat, Rishi Lulla, Benjamin Carcamo, Stanley Chaleff, Alain Charest, Frederik De Smet, Azra H. Ligon, Adrian Dubuc, Melanie Pages, Pascale Varlet, Patrick Wen, Brian Alexander, Susan Chi, Sanda Alexandrescu, Ralf Kittler, Robert Bachoo, Rameen Beroukhim, Pratiti Bandopadhayay, Keith L. Ligon

CANCER RESEARCH (2023)

Article Oncology

Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers

Kenneth E. Huffman, Long Shan Li, Ryan Carstens, Hyunsil Park, Luc Girard, Kimberley Avila, Shuguang Wei, Rahul Kollipara, Brenda Timmons, Jessica Sudderth, Nawal Bendris, Jiyeon Kim, Pamela Villalobos, Junya Fujimoto, Sandra Schmid, Ralph J. Deberardinis, Ignacio Wistuba, John Heymach, Ralf Kittler, Esra A. Akbay, Bruce Posner, Yuzhuo Wang, Stephen Lam, Steven A. Kliewer, David J. Mangelsdorf, John D. Minna

Summary: Glucocorticoid receptor (GR) is an important target for anti-cancer therapies in lymphoid cancers. This study finds that a dexamethasone-GR mediated anti-cancer response exists in a subset of aggressive non-small cell lung cancers (NSCLCs) with STK11/LKB1 mutations. The high expression of carbamoyl phosphate synthase 1 (CPS1) is strongly linked to LKB1 mutations and serves as a predictor of NSCLC dexamethasone sensitivity.

FRONTIERS IN ONCOLOGY (2023)

No Data Available